...
首页> 外文期刊>World journal of gastroenterology : >Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease
【24h】

Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease

机译:小儿炎症性肠病的营养状况,身体成分和生长情况的最新进展

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Growth and nutritional status are important issues in paediatric inflammatory bowel disease (IBD). While linear growth is easy to assess, nutritional status is more complicated, with reports often compromised by the use of simple measures, such as weight and the body mass index, to assess nutritional status rather than more appropriate and sophisticated techniques to measure body composition. This review is an update on what is currently known about nutritional status as determined by body composition in paediatric IBD. Further, this review will focus on the impact of biologics on growth in paediatric IBD. Significant lean mass deficits have been reported in children with IBD compared with controls, and there is evidence these deficits persist over time. Furthermore, data imply that gender differences exist in body composition, both at diagnosis and in response to treatment. With respect to growth improvements following treatment with biologics, there are conflicting data. While some studies report enhancement of growth, others do not. The relationship between disease severity, impaired growth and the requirement for biologics needs to be considered when interpreting these data. However, key features associated with improvements in growth appear to be successful clinical response to treatment, patients in early stages of puberty, and the presence of growth failure at the onset of treatment. (c) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
机译:生长和营养状况是小儿炎症性肠病(IBD)的重要问题。虽然线性增长很容易评估,但营养状况却更为复杂,报告通常由于使用简单的方法(例如体重和体重指数)来评估营养状况而受到损害,而不是使用更合适,更复杂的技术来测量身体成分。这篇评论是对目前由小儿IBD的身体成分决定的营养状况的最新信息。此外,本文将重点关注生物制剂对小儿IBD生长的影响。据报道,与对照组相比,IBD患儿的瘦肉量缺乏明显,并且有证据表明这些缺乏随着时间的推移持续存在。此外,数据暗示在诊断和对治疗的反应中,身体成分存在性别差异。关于用生物制剂治疗后生长的改善,有相互矛盾的数据。有些研究报告增长有所提高,而另一些则没有。解释这些数据时,应考虑疾病严重程度,生长受损和对生物制剂的需求之间的关系。但是,与生长改善相关的关键特征似乎是对治疗的成功临床反应,青春期早期的患者以及治疗开始时出现生长衰竭。 (c)2014百事登出版集团有限公司。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号